Welcome to our dedicated page for Editas Medicine news (Ticker: EDIT), a resource for investors and traders seeking the latest updates and insights on Editas Medicine stock.
Editas Medicine, Inc. develops genome editing medicines using CRISPR systems for serious diseases. Company news centers on its in vivo pipeline, including EDIT-401, an LDLR-targeted development candidate designed to treat hyperlipidemia by increasing LDLR protein expression and reducing LDL cholesterol.
Recurring updates include quarterly financial results, business highlights, scientific conference presentations, preclinical data for EDIT-401, intellectual property developments involving CRISPR/Cas9 patent interference, and investor conference participation. The company also reports on pipeline prioritization and its licensed Cas12a and Cas9 patent estates for human medicines.
Editas Medicine (Nasdaq: EDIT) reported second quarter 2026 results and business updates, highlighting progress of its in vivo CRISPR candidate EDIT-401 for hyperlipidemia and Heterozygous Familial Hypercholesterolemia. The company is on track to submit an Australian Clinical Trial Notification in August 2026 and plans to start a two-part Phase 1/2 trial, with a data update expected in Q1 2027 and Part 1 topline data in 2027.
Preclinical non-human primate data showed ~90% or greater mean reductions in LDL-C, Lp(a), and ApoB with a single EDIT-401 dose, sustained for about six months with no adverse clinical observations at 1.5 mg/kg. Editas completed a $125 million public equity and warrant offering, with potential additional gross proceeds of ~$194.4 million upon full warrant exercise. Cash and equivalents rose to $211.6 million at June 30, 2026, extending cash runway into the second half of 2028. Q2 2026 net loss narrowed to $18.2 million ($0.15 per share) from $53.2 million ($0.63) a year earlier, as revenue increased to $11.9 million and restructuring and impairment shifted to a $1.3 million benefit.
Editas Medicine (Nasdaq: EDIT) appointed Patrick T. Ellinor, M.D., Ph.D., to its Board of Directors, effective August 6, 2026, while Elliott Levy, M.D., will step down as an independent director. According to Editas, Dr. Ellinor is a recognized leader in cardiovascular medicine and human genetics whose work has identified novel therapeutic targets and advanced translation of genetic discoveries into potential therapies.
He currently serves as Executive Director of the Mass General Brigham Heart and Vascular Institute and Director of the Cardiovascular Disease Initiative at the Broad Institute. Editas highlighted that his expertise in integrating genetics, genomics, AI, and therapeutic discovery is expected to support advancement of EDIT-401 for the potential treatment of hyperlipidemia and the company’s in vivo gene editing platform.
Editas Medicine (Nasdaq: EDIT) updated the timing of its appearance at the 2026 Jefferies Global Healthcare Conference. The company will now present on June 4, 2026 at 2:00 p.m. ET in New York, with a live webcast and 30-day replay via its investor website.
Editas Medicine (Nasdaq: EDIT) priced an underwritten public offering of 55,555,556 common shares plus accompanying warrants to purchase 55,555,556 shares at a combined price of $2.25 per unit, for expected gross proceeds of about $125 million before expenses.
The common stock warrants are immediately exercisable at $3.50 per share (or $3.4999 for pre-funded warrants) and could generate up to an additional $194.4 million in gross proceeds if fully exercised. The offering, sold entirely by Editas Medicine, is expected to close on or about May 27, 2026, subject to customary conditions.
Editas Medicine (Nasdaq: EDIT) commenced a proposed underwritten public offering of common stock (or pre-funded warrants) and accompanying warrants, with all securities sold by the company.
The offering, managed by Cantor and Wells Fargo Securities, uses an effective Form S-3 shelf registration and is subject to market conditions, with final size and terms not yet set.
Editas Medicine (Nasdaq: EDIT) reported new preclinical data for its in vivo gene-editing candidate EDIT-401 presented at the 94th European Atherosclerosis Society Congress.
A single dose in non-human primates produced ~≥90% mean reductions in LDL-C, Lp(a), and ApoB, with rapid, dose-dependent effects and highly correlated changes linked to LDLR upregulation.
Editas is running GLP toxicology studies, reporting EDIT-401 was well-tolerated at 1.5 mg/kg, and received positive FDA pre-IND feedback. The company plans an Australian CTN by mid-2026 and aims for early in vivo human proof-of-concept data by end-2026.
Editas Medicine (Nasdaq: EDIT) reported new preclinical data for EDIT-401, its in vivo CRISPR candidate for hyperlipidemia, at the 2026 ASGCT and TIDES meetings. A single dose in non-human primates produced ≥90% mean LDL-C reduction with ≥6-fold hepatic LDLR increase and maintained LDL-C lowering for ~6 months across 1.5–3.0 mg/kg.
According to the company, EDIT-401 showed a promising preclinical safety profile at 1.5 mg/kg, hepatocyte-targeted delivery with undetectable oocyte delivery, and dose-dependent LDL-C reduction. Mouse data with EDIT-401(mu) suggest dose adjustments may not be needed for HeFH patients. DNA-LLM models also supported broader in vivo upregulation applications.
Editas Medicine (Nasdaq: EDIT) reported Q1 2026 results and business updates on May 5, 2026. Key highlights: EDIT-401 showed >90% mean LDL-C reduction in preclinical studies and remains on track for a first-in-human study later in 2026 with early proof-of-concept data by year-end. Cash was $123.6M as of March 31, 2026, with runway into Q3 2027. Q1 net loss was $25.0M ($0.26/share); R&D expense was $17.6M and G&A was $10.2M. The USPTO reaffirmed a PTAB decision in favor of the Broad Institute on March 26, 2026.
Editas Medicine (Nasdaq: EDIT) announced five accepted abstracts presenting new preclinical data for EDIT-401, its lead in vivo CRISPR development candidate for hyperlipidemia, at ASGCT, TIDES USA, and EAS in May 2026. Presentations include oral and poster sessions reporting LDLR upregulation and LDL-C lowering in animal models.
Abstracts will be available on conference sites and presentations posted on the company website during the meetings.
Editas Medicine (Nasdaq: EDIT) said the U.S. Patent and Trademark Office has reaffirmed the PTAB’s decision favoring the Broad Institute on inventorship in the CRISPR/Cas9 interference, marking the third PTAB ruling finding Broad first to invent CRISPR/Cas9 in eukaryotic (including human) cells.
Editas holds exclusive licenses to the CRISPR/Cas9 patents at issue and says its broader CRISPR/Cas9 and CRISPR/Cas12a intellectual property portfolio across multiple jurisdictions remains intact; CVC retains the right to appeal to the CAFC.